Song W, Chen J, Redinger R N
Department of Medicine, University of Louisville, School of Medicine, KY 40292, USA.
J Investig Med. 1998 Dec;46(9):460-9.
Apolipoprotein A-I within high density lipoprotein (HDL) plays a significant role in the process of reverse cholesterol transport from peripheral tissues to the liver. However, additional roles are not well defined for it in hepatic cholesterol metabolism. We have previously shown in the hamster that dietary cholesterol supplementation resulted in enhancement of apolipoprotein A-I (Apo A-I) in secreted nascent hepatic very low density lipoprotein (VLDL), suggesting that apolipoprotein A-I itself may play a role in hepatic lipoprotein secretion.
Using the isolated hamster liver with Apolipoprotein A-I perfusion, we then examined the hypothesis that Apo A-I alone or in association with phosphotidylcholine (PC) i.e., Apo A-I/PC as a HDL-like particle, has effects upon hepatic lipoprotein and bile secretion. Ultracentrifugation was performed on perfusate samples at 3 hours on control vs treated livers (Apo A-I/PC, Apo A-I, or PC) to access lipid and protein concentration in VLDL, low density lipoprotein (LDL) and HDL. Four to thirty percent gradient SDS polyacrylamide electrophoresis (PAGE) and Western blot analysis were used on delipidated lipoprotein fractions and microsomes to assess apolipoproteins Apo B, A-I, II, and E.
We found that perfusion of reconstituted HDL vesicles containing human apolipoprotein A-I and PC (Apo A-I/PC) 10 mg and 10 mg, respectively, in 22 mL for 3 hours into isolated hamster liver increased cholesterol (CH) and triglyceride (TG) components in secreted HDL; 45- and 6-fold, and in LDL; 15- and 2-fold, respectively. No significant changes occurred in VLDL or in biliary lipids. Concomitantly, Apo A-I/PC perfusion increased Apo E and Apo A-II and HDL and Apo B in LDL, while Apo E decreased in VLDL. Apo A-I/PC perfusion did not change the apolipoprotein content of hepatic microsomes of the perfused liver. Perfusion of apolipoprotein A-I (without PC) or PC (without apolipoprotein A-I) had none of these effects.
These results indicate that the perfused discoidal apolipoprotein A-I/PC particle affects hepatic lipoprotein assembly and secretion, whereby both lipid and apolipoprotein components are enhanced in secreted HDL and LDL of hepatic origin.
高密度脂蛋白(HDL)中的载脂蛋白A-I在胆固醇从外周组织逆向转运至肝脏的过程中发挥着重要作用。然而,其在肝脏胆固醇代谢中的其他作用尚未明确界定。我们之前在仓鼠实验中发现,饮食中补充胆固醇会导致分泌的新生肝脏极低密度脂蛋白(VLDL)中载脂蛋白A-I(Apo A-I)增加,这表明载脂蛋白A-I本身可能在肝脏脂蛋白分泌中发挥作用。
我们利用分离的仓鼠肝脏进行载脂蛋白A-I灌注实验,检验单独的载脂蛋白A-I或与磷脂酰胆碱(PC)结合形成的类似HDL颗粒(即Apo A-I/PC)对肝脏脂蛋白和胆汁分泌的影响这一假设。在灌注3小时后,对对照组和处理组肝脏(Apo A-I/PC、Apo A-I或PC)的灌注液样本进行超速离心,以测定VLDL、低密度脂蛋白(LDL)和HDL中的脂质和蛋白质浓度。对脱脂脂蛋白组分和微粒体进行4%至30%梯度的十二烷基硫酸钠聚丙烯酰胺凝胶电泳(PAGE)和蛋白质免疫印迹分析,以评估载脂蛋白Apo B、A-I、II和E。
我们发现,将分别含有10毫克人载脂蛋白A-I和10毫克PC的重组HDL囊泡(Apo A-I/PC)在22毫升溶液中灌注到分离的仓鼠肝脏3小时,会使分泌的HDL中的胆固醇(CH)和甘油三酯(TG)成分分别增加45倍和6倍,使LDL中的CH和TG成分分别增加15倍和2倍。VLDL和胆汁脂质无显著变化。同时,Apo A-I/PC灌注会使LDL中的Apo E、Apo A-II以及HDL和Apo B增加,而VLDL中的Apo E减少。Apo A-I/PC灌注并未改变灌注肝脏微粒体中的载脂蛋白含量。单独灌注载脂蛋白A-I(不含PC)或PC(不含载脂蛋白A-I)则无上述作用。
这些结果表明,灌注的盘状载脂蛋白A-I/PC颗粒会影响肝脏脂蛋白的组装和分泌,从而使肝脏来源的分泌HDL和LDL中的脂质和载脂蛋白成分均增加。